TCON — TRACON Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $0.15m
- -$6.12m
- $12.05m
Tracon Pharmaceuticals Inc Expected To Post A Loss Of 10 Cents A Share: Earnings Preview
Brief: TRACON Pharmaceuticals Says Co Collected Previously Announced Arbitration Award From I-Mab Biopharma
Brief: Tracon Pharmaceuticals Announces Positive Results Based On Ongoing Double-Digit Objective Response Rate For Single Agent Envafolimab In The Envasarc Phase 2 Pivotal Trial
Brief: Tracon Pharmaceuticals Starts Court Proceedings To Enforce April Arbitration Award Against I-MAB For ~$23Mln
Brief: Tracon Pharmaceuticals Receives Notice Of Delisting Or Failure From Nasdaq
Brief: Tracon Pharmaceuticals Inc Files Prospectus For Offer And Resale Of Up To 5 Million Shares Of Co's Common Stock By Selling Stockholder - SEC Filing
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Tracon Pharma Reports First Quarter 2023 Financial Results
Tracon Pharmaceuticals Inc Expected To Post A Loss Of 26 Cents A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-Alphabet, First Republic Bank, Microsoft
Tracon Pharma Down After Unfavorable Ruling In Dispute With I: MAB
Brief: Tracon Pharmaceuticals Inc - Tribunal In Arbitration Against I-Mab Rendered An Award To Tracon Of About $23.0 Million
U.S. STOCKS ON THE MOVE-PepsiCo, McDonald's, Dow
Brief: Runway Growth Finance Corp Says As Of March 31, Co's Portfolio Included 59 Debt Investments And 55 Equity Investments In 49 Portfolio Companies
Brief: Tracon Pharmaceuticals Says Yet To Receive Notification Of Award In Connection With Ongoing Arbitration With I-Mab Biopharma
Brief: Tracon Pharmaceuticals Inc Files Prospectus Relates To Disposition From Time To Time Of Up To 2.2 Million Shares Of Common Stock By Selling Stockholder
Brief: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results
Tracon Pharmaceuticals Inc Expected To Post A Loss Of 27 Cents A Share: Earnings Preview
Brief: Tracon To Report Q4 And Year-End 2022 Financial Results And Provide Corporate Update On March 8, 2023